HINGHAM, Mass. - Microbot Medical Inc. (NASDAQ:MBOT) announced Monday it will present at the 25th Annual Needham Virtual Healthcare Conference, being held April 13-16.
Harel Gadot, CEO, President and Chairman, will present Wednesday at 10:15 a.m. ET. The presentation will focus on the company's LIBERTY Endovascular Robotic System, according to a press release statement.
The company said it recently completed a limited market release of the LIBERTY system in the U.S. and commenced its full market release earlier this week at the Society of Interventional Radiology Annual Scientific Meeting.
LIBERTY is described as an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. The system is designed for vascular navigation with the aim of reducing radiation exposure and physical strain.The company, valued at $161.85 million, has seen its stock rise 17.5% year-to-date despite trading above its InvestingPro Fair Value. According to InvestingPro Tips, Microbot holds more cash than debt on its balance sheet, providing financial flexibility as it scales its commercial operations. Analysts have set price targets ranging from $5 to $12 per share.
The presentation will be webcast live and accessible via the investors section on Microbot Medical's website. Company executives will also participate in one-on-one meetings with healthcare-focused institutional investors during the conference.
Microbot Medical is a commercial stage medical device company focused on endovascular procedures through robotic technology.
In other recent news, Microbot Medical announced the full market release of its LIBERTY Endovascular Robotic System in the U.S., following a successful limited market release. This development was highlighted at the Society of Interventional Radiology annual scientific meeting. The LIBERTY system, which is FDA-cleared and remotely operated, has been adopted by healthcare systems like Emory Healthcare and Tampa General Hospital for various procedures, including prostate artery embolization and liver cancer treatments. Emory Healthcare recently completed the first robotic prostate artery embolization using the LIBERTY system.
Additionally, a study evaluating the LIBERTY system was published in the Journal of Vascular and Interventional Radiology. The study, led by Dr. Francois Cornelis, focused on the system’s feasibility for arterial peripheral vascular interventions. In response to the American Medical Association’s new policies on radiation exposure, Microbot Medical emphasized the LIBERTY system’s ability to address these concerns, highlighting its potential to reduce radiation exposure for healthcare professionals. H.C. Wainwright reiterated a Buy rating for Microbot Medical, maintaining a $12.00 price target, following these advancements.